Literature DB >> 31186314

Dissecting the Stromal Signaling and Regulation of Myeloid Cells and Memory Effector T Cells in Pancreatic Cancer.

Alex B Blair1,2,3, Victoria M Kim1,2,3, Stephen T Muth1,2, May Tun Saung1,2,4, Nathalie Lokker5, Barbara Blouw6, Todd D Armstrong1,2, Elizabeth M Jaffee1,2,4, Takahiro Tsujikawa7,8,9, Lisa M Coussens8,9, Jin He1,2,3, Richard A Burkhart1,2,3, Christopher L Wolfgang1,2,3,4, Lei Zheng10,2,3,4.   

Abstract

PURPOSE: Myeloid cells are a prominent immunosuppressive component within the stroma of pancreatic ductal adenocarcinoma (PDAC). Previously, targeting myeloid cells has had limited success. Here, we sought to target the myeloid cells through modifying a specific stromal component. EXPERIMENTAL
DESIGN: A murine model of metastatic PDAC treated with an irradiated whole-cell PDAC vaccine and PDAC specimens from patients treated with the same type of vaccine were used to assess the immune-modulating effect of stromal hyaluronan (HA) degradation by PEGPH20.
RESULTS: Targeting stroma by degrading HA with PEGPH20 in combination with vaccine decreases CXCL12/CXCR4/CCR7 immunosuppressive signaling axis expression in cancer-associated fibroblasts, myeloid, and CD8+ T cells, respectively. This corresponds with increased CCR7- effector memory T-cell infiltration, an increase in tumor-specific IFNγ, and improved survival. In the stroma of human PDACs treated with the same vaccine, decreased stromal CXCR4 expression significantly correlated with decreased HA and increased cytotoxic activities, suggesting CXCR4 is an important therapeutic target.
CONCLUSIONS: This study represents the first to dissect signaling cascades following PDAC stroma remodeling via HA depletion, suggesting this not only overcomes a physical barrier for immune cell trafficking, but alters myeloid function leading to downstream selective increases in effector memory T-cell infiltration and antitumor activity. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31186314      PMCID: PMC6726532          DOI: 10.1158/1078-0432.CCR-18-4192

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  58 in total

1.  Gene Expression Omnibus: NCBI gene expression and hybridization array data repository.

Authors:  Ron Edgar; Michael Domrachev; Alex E Lash
Journal:  Nucleic Acids Res       Date:  2002-01-01       Impact factor: 16.971

2.  The structure and function of hyaluronate.

Authors:  H J ROGERS
Journal:  Biochem Soc Symp       Date:  1961

Review 3.  Cancer and the chemokine network.

Authors:  Fran Balkwill
Journal:  Nat Rev Cancer       Date:  2004-07       Impact factor: 60.716

4.  Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice.

Authors:  J P Machiels; R T Reilly; L A Emens; A M Ercolini; R Y Lei; D Weintraub; F I Okoye; E M Jaffee
Journal:  Cancer Res       Date:  2001-05-01       Impact factor: 12.701

5.  CXC chemokine ligand 12 promotes CCR7-dependent naive T cell trafficking to lymph nodes and Peyer's patches.

Authors:  Zhongbin Bai; Haruko Hayasaka; Masayoshi Kobayashi; Wenzhe Li; Zijin Guo; Myoung Ho Jang; Akihiro Kondo; Byung-il Choi; Yoichiro Iwakura; Masayuki Miyasaka
Journal:  J Immunol       Date:  2009-02-01       Impact factor: 5.422

6.  Effective depletion of regulatory T cells allows the recruitment of mesothelin-specific CD8 T cells to the antitumor immune response against a mesothelin-expressing mouse pancreatic adenocarcinoma.

Authors:  Ihid C Leao; Priya Ganesan; Todd D Armstrong; Elizabeth M Jaffee
Journal:  Clin Transl Sci       Date:  2008-12       Impact factor: 4.689

7.  Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice.

Authors:  Sunil R Hingorani; Lifu Wang; Asha S Multani; Chelsea Combs; Therese B Deramaudt; Ralph H Hruban; Anil K Rustgi; Sandy Chang; David A Tuveson
Journal:  Cancer Cell       Date:  2005-05       Impact factor: 31.743

8.  CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma.

Authors:  Akira Fukunaga; Masaki Miyamoto; Yasushi Cho; Soichi Murakami; You Kawarada; Taro Oshikiri; Kentaro Kato; Takanori Kurokawa; Masato Suzuoki; Yoshihiro Nakakubo; Kei Hiraoka; Tomoo Itoh; Toshiaki Morikawa; Shunichi Okushiba; Satoshi Kondo; Hiroyuki Katoh
Journal:  Pancreas       Date:  2004-01       Impact factor: 3.327

9.  Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation.

Authors:  Dan Laheru; Eric Lutz; James Burke; Barbara Biedrzycki; Sara Solt; Beth Onners; Irena Tartakovsky; John Nemunaitis; Dung Le; Elizabeth Sugar; Kristen Hege; Elizabeth Jaffee
Journal:  Clin Cancer Res       Date:  2008-03-01       Impact factor: 12.531

Review 10.  Central memory and effector memory T cell subsets: function, generation, and maintenance.

Authors:  Federica Sallusto; Jens Geginat; Antonio Lanzavecchia
Journal:  Annu Rev Immunol       Date:  2004       Impact factor: 28.527

View more
  26 in total

Review 1.  Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future.

Authors:  Eric S Christenson; Elizabeth Jaffee; Nilofer S Azad
Journal:  Lancet Oncol       Date:  2020-03       Impact factor: 41.316

Review 2.  Next-generation immunotherapy for pancreatic ductal adenocarcinoma: navigating pathways of immune resistance.

Authors:  Thatcher Heumann; Nilofer Azad
Journal:  Cancer Metastasis Rev       Date:  2021-09-30       Impact factor: 9.264

3.  High-dimensionality reduction clustering of complex carbohydrates to study lung cancer metabolic heterogeneity.

Authors:  Lindsey R Conroy; Josephine E Chang; Qi Sun; Harrison A Clarke; Michael D Buoncristiani; Lyndsay E A Young; Robert J McDonald; Jinze Liu; Matthew S Gentry; Derek B Allison; Ramon C Sun
Journal:  Adv Cancer Res       Date:  2022-03-18       Impact factor: 5.767

Review 4.  The Desmoplastic Stroma of Pancreatic Cancer: Multilayered Levels of Heterogeneity, Clinical Significance, and Therapeutic Opportunities.

Authors:  Yohei Masugi
Journal:  Cancers (Basel)       Date:  2022-07-05       Impact factor: 6.575

Review 5.  The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities.

Authors:  Won Jin Ho; Elizabeth M Jaffee; Lei Zheng
Journal:  Nat Rev Clin Oncol       Date:  2020-05-12       Impact factor: 66.675

6.  Disrupting a converging metabolic target turns up the immunologic-heat in pancreatic tumors.

Authors:  Won Jin Ho; Elizabeth M Jaffee
Journal:  J Clin Invest       Date:  2020-01-02       Impact factor: 14.808

7.  CD137 agonist-based combination immunotherapy enhances activated, effector memory T cells and prolongs survival in pancreatic adenocarcinoma.

Authors:  Stephen T Muth; May Tun Saung; Alex B Blair; MacKenzie G Henderson; Dwayne L Thomas; Lei Zheng
Journal:  Cancer Lett       Date:  2020-11-30       Impact factor: 8.679

8.  Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma.

Authors:  Juri Kiyokawa; Yoichiro Kawamura; Shanawaz M Ghouse; Simge Acar; Erinç Barçın; Jordi Martínez-Quintanilla; Robert L Martuza; Ramon Alemany; Samuel D Rabkin; Khalid Shah; Hiroaki Wakimoto
Journal:  Clin Cancer Res       Date:  2020-11-30       Impact factor: 13.801

9.  ERK Inhibition Improves Anti-PD-L1 Immune Checkpoint Blockade in Preclinical Pancreatic Ductal Adenocarcinoma.

Authors:  Kelly E Henry; Kyeara N Mack; Veronica L Nagle; Mike Cornejo; Adam O Michel; Ian L Fox; Maria Davydova; Thomas R Dilling; Nagavarakishore Pillarsetty; Jason S Lewis
Journal:  Mol Cancer Ther       Date:  2021-08-04       Impact factor: 6.261

Review 10.  Overcoming physical stromal barriers to cancer immunotherapy.

Authors:  Seung Woo Chung; Yunxuan Xie; Jung Soo Suk
Journal:  Drug Deliv Transl Res       Date:  2021-08-05       Impact factor: 4.617

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.